Zacks Investment Research upgraded shares of Bruker (NASDAQ:BRKR) from a hold rating to a buy rating in a research note published on Thursday, January 4th. Zacks Investment Research currently has $39.00 target price on the medical research company’s stock.

According to Zacks, “Over the past three months, Bruker has been observed to trade above the broader industry.  Of late, the company’s Scientific Instruments segment has been performing well where growth was driven by strong results within NANO and CALID groups. The company raising 2017 guidance, is indicative of brighter prospects. Moving on, the company’s strategic acquisition activity has been encouraging. In this context, the company recently announced the completion of acquisition of Germany-based MERLIN whose products can complement Bruker’s MALDI Biotyper platform. On the flip side, currency fluctuations, competitive landscape and macroeconomic headwinds continue to pose challenges for the company.”

A number of other equities research analysts also recently weighed in on BRKR. Goldman Sachs Group reiterated a sell rating and set a $24.00 price target on shares of Bruker in a research note on Tuesday, September 26th. Morgan Stanley reiterated an equal weight rating and set a $35.00 price target on shares of Bruker in a research note on Thursday, December 14th. Evercore ISI initiated coverage on shares of Bruker in a research note on Wednesday, January 3rd. They issued an in-line rating and a $36.00 target price on the stock. JPMorgan Chase & Co. upgraded shares of Bruker from an underweight rating to a neutral rating and set a $28.00 price target on the stock in a research report on Friday, November 3rd. Finally, Cowen reiterated a hold rating and set a $35.00 price target on shares of Bruker in a research report on Thursday, December 21st. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the stock. Bruker has a consensus rating of Hold and a consensus price target of $32.38.

Bruker (BRKR) opened at $35.65 on Thursday. Bruker has a 52-week low of $21.83 and a 52-week high of $36.53. The company has a market cap of $5,533.37, a P/E ratio of 30.40, a PEG ratio of 2.63 and a beta of 1.12. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60.

Bruker (NASDAQ:BRKR) last announced its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The business had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Bruker’s revenue was up 10.6% compared to the same quarter last year. sell-side analysts forecast that Bruker will post 1.19 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in BRKR. Acrospire Investment Management LLC boosted its holdings in shares of Bruker by 496.1% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock valued at $110,000 after buying an additional 3,185 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Bruker in the 2nd quarter valued at approximately $111,000. Zions Bancorporation acquired a new stake in shares of Bruker in the 3rd quarter valued at approximately $119,000. Bank of Montreal Can boosted its holdings in shares of Bruker by 346.7% in the 4th quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock valued at $128,000 after buying an additional 2,878 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Bruker by 11.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock valued at $133,000 after buying an additional 467 shares during the last quarter. 65.77% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Bruker (NASDAQ:BRKR) Upgraded at Zacks Investment Research” was originally published by Marea Informative and is the sole property of of Marea Informative. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.mareainformativa.com/2018/01/30/bruker-brkr-upgraded-at-zacks-investment-research-updated-updated-updated.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.